Skip to main content
. 2022 Apr 17;14(4):878. doi: 10.3390/pharmaceutics14040878

Table 3.

Characteristics of the studies included in the systematic review for SNP–SNP combinations of ABC and SLC transporters.

SNP Study n Age (Range) Ethnia (Country) HWE LMA Status (%) Chemotherapy Scheme Clinical Outcomes
ABCB1 + SLC
ABCB1 C3435T
rs1045642
SLCO1B1 rs4149056 (T>C)		 Megías-Vericat et al., 2017 [62] 225 52.5 (16–78) Caucasian Yes De novo Ara C + IDA
  • -

    CR, induction death: no influence

  • -

    Toxicity: TT + TT genotype ↑hepatic toxicity (p: 0.038)
ABCB1 C3435T
rs1045642
SLC22A16 rs12210538 (A>G)		 Megías-Vericat et al., 2017 [62] 225 52.5 (16–78) Caucasian Yes De novo Ara C + IDA
  • -

    CR, induction death: no influence

  • -

    Toxicity: TT + AA genotype ↑hepatic toxicity (p: 0.019), mucositis (p: 0.004), neutropenia (p: 0.034)
ABCB1 G2677T/A
rs2032582
SLCO1B1 rs4149056 (T>C)		 Megías-Vericat et al., 2017 [62] 225 52.5 (16–78) Caucasian Yes De novo Ara C + IDA
  • -

    CR, induction death: no influence

  • -

    Toxicity: TT + TT genotype ↑renal (p: 0.030), hepatic toxicity (p: 0.002)
ABCB1 G2677T/A
rs2032582
SLC22A16 rs12210538 (A>G)		 Megías-Vericat et al., 2017 [62] 225 52.5 (16–78) Caucasian Yes De novo Ara C + IDA
  • -

    CR, induction death: no influence

  • -

    Toxicity: TT + AA genotype ↑hepatic toxicity (p: 0.008)
ABCB1 G2677T/A
rs2032582
SLC22A16rs714368 (A>G)		 Megías-Vericat et al., 2017 [62] 225 52.5 (16–78) Caucasian Yes De novo Ara C + IDA
  • -

    CR, induction death: no influence

  • -

    Toxicity: TT + AA genotype ↑renal (p: 0.026), hepatic toxicity (p: 0.008)
ABCB1 C1236T
rs1128503
SLCO1B1 rs4149056 (T>C)		 Megías-Vericat et al., 2017 [62] 225 52.5 (16–78) Caucasian Yes De novo Ara C + IDA
  • -

    CR: no influence

  • -

    Induction death: TT + TT genotype ↑induction death (p: 0.018)

  • -

    Toxicity: TT + TT genotype ↑renal (p: 0.048), hepatic toxicity (p < 0.001)
ABCB1 haplotype 1
SLCO1B1 rs4149056 (T>C)		 Megías-Vericat et al., 2017 [62] 225 52.5 (16–78) Caucasian Yes De novo Ara C + IDA
  • -

    CR: no influence

  • -

    Induction death: TT/TT/TT + TT genotype ↑induction death (p: 0.009)

  • -

    Toxicity: TT/TT/TT + TT genotype ↑renal (p: 0.017), hepatic toxicity (p < 0.001)
ABCB1 haplotype 1
SLC22A16 rs12210538 (A>G)		 Megías-Vericat et al., 2017 [62] 225 52.5 (16–78) Caucasian Yes De novo Ara C + IDA
  • -

    CR, induction death: no influence

  • -

    Toxicity: TT/TT/TT +AA genotype ↑renal (0.036), hepatic toxicity (p: 0.015)
ABCB1 haplotype 1
SLC22A16 rs714368 (A>G)		 Megías-Vericat et al., 2017 [62] 225 52.5 (16–78) Caucasian Yes De novo Ara C + IDA
  • -

    CR, induction death: no influence

  • -

    Toxicity: TT/TT/TT +AA genotype ↑ hepatic toxicity (p: 0.001)
ABCC1 + SLC
ABCC1 rs4148350
SLCO1B1/SLC22A16 		Megías-Vericat et al., 2017 [62] 225 52.5 (16–78) Caucasian Yes De novo Ara C + IDA
  • -

    CR, induction death: no influence

  • -

    Toxicity: no influence
ABCC2 + SLC
ABCC2 rs8187710
SLCO1B1/SLC22A16 		Megías-Vericat et al., 2017 [62] 225 52.5 (16–78) Caucasian Yes De novo Ara C + IDA
  • -

    CR, induction death: no influence

  • -

    Toxicity: no influence
ABCG2 + SLC
ABCG2
rs2231142 (C>A)
SLC22A16 rs714368 (A>G)		 Megías-Vericat et al., 2017 [62] 225 52.5 (16–78) Caucasian Yes De novo Ara C + IDA
  • -

    CR, induction death: no influence

  • -

    Toxicity: AC + AA genotype ↑cardiac toxicity (p: 0.033)

Abbreviations: AML: acute myeloid leukemia; CR: complete remission; HWE: Hardy–Weinberg equilibrium; IDA: idarubicin; NR: not reported; OS: overall survival. 1—The ABCB1 haplotype included the polymorphisms rs1128503, rs1045642 and rs2032582.